The ICGM® system is designed to dramatically impact the lives of people with diabetes by offering the benefits of continuous glucose monitoring while minimizing user burden, reducing maintenance, and preserving a nearly undisturbed body image.
• The system requires no needle insertion, no through-the-skin sensor and no skin-adhered components that need to be changed every few days or every week.
• The innovative system is designed for stability and is expected to require only infrequent calibration by SMBG finger-stick.
• The fully inserted sensor is expected to reside for one year (or longer) in the subcutaneous tissue and will free individuals from the burden of maintaining obtrusive skin-attached components, that can be sufficient impediment to normal active lifestyles.
The user-centric GlySens solution is intended to provide easy, unobtrusive, worry-free glucose monitoring and empower individuals with real-time information, while freeing them to live life on their own terms.
The Eclipse ICGM System is comprised of an insertable glucose sensor paired to an external receiver (display device). The sensor is designed for exceptional longevity occupying a small space in the subcutaneous tissue. It combines a novel differential measurement technique that is designed to reduce secondary artifacts with careful engineering for reduced foreign body response. The mobile display is designed to offer at-a-glance, real-time glucose information highlighting trends, with alerts regarding hypo- or hyperglycemic excursions. The display device also is designed to store historic blood glucose values and make these data available to download for retrospective trend analysis. It is anticipated to be compatible with other diabetes devices in order to display data in context of meals and activities essential for diabetes self-management.
The long term ICGM sensor is designed to be inserted by a brief outpatient procedure under local anesthesia and then measure interstitial fluid glucose levels in adults with diabetes for its operating life.
The GlySens ICGM System is Intended to Enable Improved Glucose Management
Continuous glucose monitoring (CGM) has been demonstrated to improve patient outcomes. A landmark study by the Juvenile Diabetes Research Foundation (JDRF) in 2008, concluded that individuals using continuous glucose monitoring devices experienced significant improvement in glucose control, which is known to lower their risks for serious complications.(1) Use of continuous glucose monitoring has also been shown to durably improve outcomes for people with type 2 diabetes.(2) Because the Eclipse ICGM system is designed to provide 24/7 information over very long durations and is expected to be convenient and unobtrusive, it is anticipated that it will enable significantly more people with diabetes to benefit from the improved outcomes associated with long term continuous monitoring. Reducing the user burden is an approach that allows the proprietary technology to seamlessly work for individuals rather than requiring them to adapt and work to incorporate any currently marketed CGM technologies.
1. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes.” The New England Journal of Medicine. 359. 2008 2. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012 Jan;35 (1):32-38
3931 Sorrento Valley Blvd Suite 110 San Diego, CA 92121